Merck's drug Pimicotinib for the treatment of tenosynovial giant cell tumor has received acceptance for its market authorization application

On June 10th, Merck announced that the Center for Drug Evaluation of the National Medical Products Administration of China has officially accepted its application for marketing authorization of the innovative Class 1 drug Pimicotinib, intended for adult patients with giant cell tumor of the tendon sheath requiring systemic treatment. Zhou Hong, Global Executive Vice President of Merck Pharmaceuticals and Head of China and International Markets, stated that the company is simultaneously advancing its application for marketing authorization to the U.S. FDA and plans to submit applications in other markets successively